drugset / Trial / NCT01168336
Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects
RandomizedParallel-groupTriple-blind
Summary
The study aims to evaluate the safety and pharmacokinetics of extended release and standard formulations of betahistine when administered as monotherapy and as compared to their safety and pharmacokinetics when co-administered with olanzapine and to determine potential dose limiting toxicities and/or drug-drug interactions affecting the pharmacokinetics or safety of either medication, with particular emphasis on somnolence and weight gain secondary to olanzapine treatment
Timeline
- Start
- 2010-07
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Betahistine | Small molecule | 24 mg | — |
| Subject | Betahistine | Small molecule | 32 mg | — |
Indications
No indication recorded.